FREE DELIVERY ON ORDERS OVER $50

Uncategorized

Impact of FDA Approval of Infigratinib on the Field of Cholangiocarcinoma Treatment

Pharmacy Times interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, on the phase 2 trial results that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or …

Impact of FDA Approval of Infigratinib on the Field of Cholangiocarcinoma Treatment Read More »

PRESCRIPTIONS
SPECIALTY PHARMACY
SERVICE & CARE
OVER THE COUNTER
SUPPLEMENTS
SKINCARE
PERSONAL CARE
RESOURCES

Get started with Local Health

Skip to content